

# A Review on Different Synthetic Route and the Medicinal Applications of 2-(3-(Dimethylamino)Propyl) Isoindoline-1,3-Dione Derivatives

Rajesh Kumar Das\*, and Sahin Reja

Department of Chemistry, University of North Bengal, Darjeeling, West Bengal, India

## Abstract


2-(3-(Dimethylamino)Propyl)Isoindoline-1,3-Dione (DAPID) derivatives have been obtained by the reaction of the phthalic acid anhydride derivatives with N, N dimethyl propyl amine derivatives. The yield of DAPID type derivative was 60% by classical way which was carried out in our laboratory. But when this reaction was carried out by modern way i.e. microwave enhance method, then the yield was 85% to 91% with short time. 3-(1,3-dioxoisindolin-2-yl)-N,N-dimethylpropan-1-ammonium perchlorate (DIDAP) derivatives have been obtained by the reaction of 2-(3-(Dimethylamino)Propyl)Isoindoline-1,3-Dione (DAPID) derivatives with salt. The DIDAP compound was synthesized in a different route followed by able to show it's excellent anticancer activity against hepatomas Hep G2 Cell line.

**Keywords:** DAPID • DIDAP • Biocidal activity

## Introduction

At the present time, the most serious public health problems in the world are cancerous disease [1-3]. Cancer is a big clinical challenge to human beings causing demolition from high malady and mortality rates. Among various types of tissue originated cancers, liver cancer is one of the damning and investive cancers in children younger than 5 years of age worldwide but also the fifth record common cancer in males and the seventh record common cancer in females, and is the third significance cause of cancer-related death worldwide [4-8]. In spite of advances in liver cancer treatment, it is one of the most tough cancers to treat. For patients first stage Hepatocellular Carcinoma (HCC), surgery, local destructive therapies, and liver replacement take remedial potential. However, repetition of HCC is a major problem after remedial treatment, reaching an incidence of more than 70% at 5 yr. Even in first stage patients, small HCC (<3 cm) receiving surgery, the 5 yr survival rate is not satisfactory (47% to 53%). Typically, HCC is mostly diagnosed at a primary stage, and many patients with primary stage are not eligible for the remedial therapies. Furthermore, customary systemic chemotherapy shows low working efficiency and samill survival benefits [9]. The approval of a multikinase vanquisher, sorafenib, has shown some progressive benefit in patients with primary HCC and conserved liver function, highlighting a promising molecular targeted strategy for primary HCC. Solution of liver cancer is now multidisciplinary, and multi model

treatment options are chosen generally on an individualized basis according to the complex interplay of tumor stage and the extent of underlying liver disease, as well as the patient's overall general health. There are various recommendations for the managing of liver cancers across the specialties and geographic areas such as major management of liver cancer guidelines from the United States National Comprehensive Cancer Network (NCCN), Europe (European Association for the Study of the Liver-European Organization for Research and Treatment of Cancer (EASLEORTC)), and Asia (consensus statement from the Asian Oncology Summit 2009 (AOS)) [10].




\*Address to Correspondence: Rajesh Kumar Das, Department of Chemistry, University of North Bengal, Darjeeling, West Bengal, India, Tel: 7318705076; E-mail: rajeshnbu@gmail.com

**Copyright:** © 2021 Das RK, et al. This is an open-access article distributed under the terms of the creative commons attribution license which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

**Received:** 02 December, 2021; **Accepted:** 10 December, 2021; **Published:** 22 December, 2021;

**Figure 1.** Synthesis pathway of the compounds.

Though most popular marketable anticancer drugs are essentially heterocyclic organic compounds and natural products, but recently metal complexes are going to much attention in anticancer research [11]. Cis-platin discovery was breakthrough in 1965 by Rosenberg et al. . This discovery has been showed a new branched of metal based anticancer drug in current anticancer drug discovery. This was successfully moved to the clinical support of many second generation platinum drugs such as oxalopatin, nedaplatin, carboplatin and other metal complexes for treatment of a diversity of cancers in several countries [12]. However the role of metal complexes in oncology was significantly good but they have been found to be associated with severe toxicity issues. So the rational experimental work on ligand design and synthesis of metal complex for targeting of particular protein part is active research area in bio-organometallic and medicinal chemistry. The synthesis of coordination compound with rationally designed architectures of ligand structures have distinct power to transfer cytotoxic metals to the specific enzymes, proteins or cell organelles and then the toxicity of metal complex is reduced [13-19]. The novel frameworks with O, N and S hetero donar ligands are going to much responsiveness in experimental anticancer drug design. Among the various metal coordination compounds, the transition metal complexes with Schiff base type ligands have shown a great potential anticancer activity such as pthalimide and indoline derivative ligand have attracted medicinal chemists due to their easy availability, fast optimization as well as presence of biologically active hetero nucleus which is showing biological and pharmaceutical activities. These model studies have proved to be useful in understanding the role of metal ions in specified coordination geometries signifying the course and nature of reactions in a particular system [20-25].

**Figure 2.** Synthesis pathway of the 8 compound.


In the midst, thalidomide is a multi-target drug that affects several cellular processes, including peptidase inhibition, (Cyclooxygenase) COX inhibition, glucosidase inhibition and androgen receptor antagonism. Research studies on the structure activity relationship (SAR) of the metabolites and correspondents of thalidomide have revealed that the phthalimide ring system is an essential pharmacophoric fragment. Phthalimide (isoindoline-1,3-dione) has usually been employed in the design of potential antitumor, immunomodulatory, antiangiogenic, anti-microbial and anti-inflammatory drug candidates [26]. Further, heterocyclic hits are of considerable utility in synthetic medicines or pesticides and biochemical effects. Heterocycles containing pyrazole, imidazo[1,2-b]-pyrazole, pyrazolopyrimidine, pyrazolo-triazine scaffolds exhibit versatile biological properties such as anti-inflammatory, antifungal, antioxidant, antitumor and immunosuppressive agents. Hence,

molecular hybridization strategy via introduction of different pharmacophoric fragments might improve the biological activity of phthalimide derivatives [27].

## Synthesis


### Different synthesis procedure of 2-(3-(dimethylamino)isoindoline-1,3-dione (DAPID) derivatives

The organic chemists synthesized of 2-(3-(dimethylamino)propyl)isoindoline-1,3-dione (DAPID) derivatives by different procedure [28-30]. 3-(N, N-dimethylamino)-propylphthalimide and the corresponding methylphthalimides 1 and 2 were obtained by conversion of two molecules of the phthalic acid anhydride derivatives with N, N dimethyl propyl amine derivatives. To achieve the phthalimides 3 and 4, phthalic acid anhydride and methylphthalic acid anhydride, respectively, were refluxed in the presence of 1,3-diamino-N, N-2,2-tetramethylpropane in toluene using a water separator (Figure 1). The compound 16 was prepared by Abdel-Hafez et.al. according to Figure 4. At first, Phthalic anhydride (0.5 g), 1.1 eq. of the appropriate amine were added to a 50 mL round-bottomed flask equipped with a reflux condenser. Then, the mixture was heated to gentle boiling at 150~250 ~ for between 5-15 min. After the reaction, the reaction mixture was cooled and then benzene (30 mL) was added before solidification to form a slurry mixture. Finally, the precipitate was filtered, washed twice with water, and the crude material was crystallized from light petrol ether 60-80°C [31-36].


**Figure 3.** Synthesis pathway of phthalimides derivatives molecules.

The compound 16 also was prepared by Teresa Borowiak et.al. according to Figure 5 but this process was different. At first, N, N-


Dimethyl-3-phthalimidopropylamine was obtained by the reaction of a commercially available N, N-dimethylpropyl-1,3-diamine with phthalic anhydride in acetic acid (Figure 5) [37]. Then, the reaction mixture was heated under reflux for 4 h. The product was purified by method given by B. Brycki et.al. The formation of the imide 16 was published as both a thermal and a microwave-enhanced method (Figure 8). The reaction time was shortened (from hours to minutes) and the yield was improved with microwaves from 85% to 91%. Recently we synthesized compound 16 by classical way with 60% yield [38-41]. At first, 5 ml toluene solution of isobenzofuran-1,3-dione (1.0 mmol, 0.148 g) was added in the stirring 5 ml toluene solution of N1, N1-dimethylpropane-1,3-diamine (1.1 mmol, 0.112 g) followed by P-Toluenesulfonic Acid (PTSA) (50 mg/g) and the reaction was stirred at reflux for 6 h. The formation of the product was examined by running TLC. The reaction mixture was cooled to room temperature and solvent was removed to get the crude [42-45]. The crude was diluted with DCM (Dichloromethane) and washed with water followed by NaHCO<sub>3</sub> solution (to remove PTSA and acid product). The solvents were dried over anhydrous sodium sulfate, filtered and solvents were removed to get the crude. The crude was purified by silica gel column chromatography using DCM to 5% MeOH in DCM (Figure 11).




**Figure 4.** Synthesis pathway of phthalimides derivative molecule 16.



**Figure 5.** Synthesis different pathway of phthalimide derivative molecule 16.




**Figure 6.** Synthesis pathway of phthalimide derivative molecule 17.



**Figure 7.** Synthesis pathway of phthalimide derivative molecule 18.


### Synthesis procedure of different type of 3-(1,3-dioxoisindolin-2-yl)-N, N-dimethylpropan-1-ammonium perchlorate (DIDAP) derivatives

The organic chemists also synthesized of different type of 3-(1,3-dioxoisindolin-2-yl)-N,N-Dimethylpropan-1-Ammonium Perchlorate (DIDAP) derivatives by the reaction of 2-(3-(Dimethylamino)Propyl)Isindoline-1,3-Dione (DAPID) derivatives with salt. Phthalimide derivatives 1a and 3a were obtained by conversion of two molecules of the phthalimide derivatives with dibromohexane. Conversion of two molecules of 3 and 4, respectively, with dibromohexane gave the symmetrical compounds 1c and 3c. To obtain the nonsymmetrical compounds, the phthalimides 1, 3, and 4 first have to be alkylated by using an excess of dibromohexane without any reaction solvent to achieve 5, 6, and 7, respectively [46-48]. Alkylation of 3 with 5, 2 with 6, 1 with 7, and 2 with 7 by refluxing in acetonitrile gave 1b, 2a, 2b, 2c, and 3b, respectively (Figure 1). The above compounds were prepared by Alexandra Raasch et.al. Seraina Duda-Johner et.al, Compound 8 was prepared in four-step syntheses according to Figure 2 mechanism. The synthesis of the phthalimides derivatives characterized by an unilateral succinimide 10 was already reported by Bender et al. The synthesis of an unilateral trans substituted cyclohexanedicarboxylic acid imide compound 9 was performed in analogy to Staudt et al. by alkylation of N,N-dimethylaminopropylphthalimide with dibromohexane and connecting the monobromo compound with the corresponding dimethylaminopropyl cyclohexanedicarboxylic acid imide [49].




**Figure 8.** Synthesis different pathway of phthalimide derivative molecule 16.

Compound 11 missing the second imide moiety was obtained by alkylation of dimethylaminopropylphthalimide with the corresponding amino-substituted bromohexane which was achieved by refluxing dibromohexane and N-ethyl dimethylamine in ethanol for 20 h. The monoquaternary compounds 12-15 can be easily obtained by alkylation of dimethyl amino propyl phthalimide with the corresponding iodo- or bromoalkane (Figure 3). The multistep synthesis of the 15 starting from pipercolic acid has been recently reported by Holzgrabe, U et.al. The Teresa Borowiak et.al. Prepared N, N-Dimethyl-3-phthalimidopropylamine acetate (Figure 6) by reaction of equimolar amounts of N, N-dimethyl-3-phthalimidopropylamine and acetic acid in anhydrous ethanol [50].



**Figure 9.** Synthesis pathway of phthalimide derivative molecule 19.


The product was purified by crystallization from hexane. Yield 65%, mp 40-41°C. The Teresa Borowiak et.al also prepared N, N-Dimethyl-3-phthalimidopropylammonium hydrochloride (Figure 7) was obtained by reaction of N, N-dimethyl-3-phthalimidopropylamine with equimolar amount of hydrochloric acid in anhydrous ethanol. The product was crystallized from anhydrous ethanol. Yield 65%, mp 203-205°C [51]. Phthalimide derivative 19 was synthesized in the classical way (time 2 h, yield 80%) and but in a microwave oven (time 30 min, yield 91%). N, N-dimethyl(carboethoxymethyl)-3-phthalimidopropylammonium chloride dihydrate (20) was prepared by reaction of equimolar amounts of N, N-dimethyl-3-phthalimidopropylamine and ethyl chloroacetate acid in anhydrous ethanol. The product was purified by crystallization from ethanol. N, N-dimethyl(carboxymethyl)-3-phthalimidopropylammonium hydrochloride was prepared by reaction equimolar amounts of N, N-dimethyl-3-phthalimidopropylamine and chloroacetic acid in anhydrous ethanol. The product was purified by crystallization from ethanol [52]. Recently we synthesized 3-(1,3-Dioxoisindolin-2-yl)-N,N-Dimethylpropan-1-Ammonium Perchlorate (DIDAP). At first methanolic solution (2 ml) of sodium perchlorate (0.5 mmol, 0.061 g) was added in a stirred methanolic solution (2 ml) of ligand 16 (0.5 mmol, 0.116 g) and the reaction was stirring for 30 min. Then 5 ml of acetonitrile solution was added and the reaction was stirring for another one hour. The reaction mixture was kept few days for crystallization purpose. After 15 days a colorless needle shaped crystal was obtained. Yield: 80% [53].



**Figure 10.** Synthesis pathway of phthalimide derivative molecules 20 and 21.

## Application

Now a days, toxicity and resistance play an important role in drug development for the treatment of diseases due to microbes, helminthes and insects. Thus there is still a search for new antimicrobial, anthelmintic and insecticidal agents. N-Mannich bases derived from phthalimide analogous have been extensively used in medicinal chemistry owing to their wide range of biological applications reported in literature. Phthalimide is a colorless solid aromatic imide in which two carbonyl groups bound to an amine functional moiety. It is a very important starting synthone for organic synthetic chemists to prepare diverse biologically active molecules. Numbers of phthalimide derivatives have been synthesized incorporated with interesting biological activities and liquid phase crystalline properties [59], as well as find varied applications in industrial field. Phthalimide and its derivatives have received much attention due to its versatile biological and pharmaceutical activities such as antimicrobial antihypertensive anti-viral, antitumor, anti-inflammatory agents as a inhibitors of HIV-I integrase and serve as ligands to form bioactive metal complexes.



**Figure 11.** Synthesis different pathway of phthalimide derivative molecule 16 and 22.

Compound 2-(3-(Dimethylamino)Propyl)Isoindoline-1,3-Dione (DAPID) showed higher protective indices (TD50/ED50) than sodium valproate, indicating their maximum anticonvulsant protection is achieved in non-neurotoxic doses. When 2-(3-(Dimethylamino)Propyl)Isoindoline-1,3-Dione (DAPID) react with sodium perchlorate (salt) produced 3-(1,3-Dioxoisindolin-2-yl)-N,N-Dimethylpropan-1-Ammonium Perchlorate (DIDAP), then the compound DIDAP showed in vitro anticancer activity against human hepatoma cell line Hep-G2 using Sulforhodamine B (SRB) assay.

## Conclusion

Synthetic heterocyclic compound continue to be a hot topic in the medicinal chemistry as well as in the bioinorganic field as most popular marketable anticancer drugs are essentially heterocyclic organic compounds and natural products, but recently metal complexes are going to much attention in anticancer research. Earlier DAPID was synthesised in various path by different scientist and anticonvulsant activity was only mentioned while DIDAP was synthesised but they did not find out any anticancer activity. We are, the first team, able to show the anticancer activity of the synthesised DIDAP complex and prepared the said compound in a different route. In this mini review, our main motive is to highlight the different synthetic procedure of phthalimide type heterocycle which act as biological activity.



## Declaration of Competing Interest

The authors have no conflicts of interest to declare the content of this article.

## Acknowledgements

The authors are grateful to the Departmental Special Assistance Figures under the University Grants Commission, New Delhi and Head, all the members, Department of Chemistry, University of North Bengal, Darjeeling, India, for providing various facilities in connection with this review work.

## References

- Xue, Si-tu, Guo Hui-fang, Liu Mei-jie, and Jin Jie, et al. "Synthesis of a Novel Class of Substituted Benzothiophene or Benzofuran Derivatives as BMP-2 Up-Regulators and Evaluation of the BMP-2-Up-Regulating Effects In Vitro and the Effects on Glucocorticoid-Induced Osteoporosis in Rats." *Euro J Med Chem* 96 (2015): 151-161.
- Lin, Quan-Jun, Yang Feng, Jin Chen, and Fu De-Liang. "Current Status and Progress of Pancreatic Cancer in China." *World J Gastroenterol* 21 (2015): 7988.
- Appelbaum, P C, and Hunter P A. "The Fluoroquinolone Antibacterials: Past, Present and Future Perspectives." *Int J Antimicrob Agents* 16 (2000): 5-15.
- Ma, Xiaomei, and Yu Herbert. "Cancer Issue: Global Burden of Cancer." *Yale J Biol Med* 79 (2006): 85.
- Kranz, Dominique, and Dobbstein Matthias. "A Killer Promoting Survival: P53 as a Selective Means to Avoid Side Effects of Chemotherapy." *Cell Cycle* 11 (2012): 2053-2054.
- Darbari, Anil, Sabin Keith M, Shapiro Craig N, and Schwarz Kathleen B. "Epidemiology of Primary Hepatic Malignancies in US Children." *Hepatology* 38 (2003): 560-566.
- Liu, Chun-Yu, Chen Kuen-Feng, and Chen Pei-Jer. "Treatment of Liver Cancer." *Cold Spring Harbor Perspectives Med* 5 (2015): a021535.
- Rosenberg, Barnett, Vancamp Loretta, Trosko James E, and Mansour Virginia H. "Platinum Compounds: A New Class of Potent Antitumor Agents." *Nature* 222 (1969): 385-386.
- Ndagi, Umar, Mhlongo Ndumiso, and Soliman Mahmoud E. "Metal Complexes in cancer Therapy-an Update from Drug Design Perspective." *Drug Design Deve Ther* 11 (2017): 599.
- Gasser, Gilles, Ott Ingo, and Metzler-Nolte Nils. "Organometallic Anticancer Compounds." *J Med Chem* 54 (2011): 3-25.
- Konkankit, Chilaluck C, Marker Sierra C, Knopf Kevin M, and Wilson Justin J. "Anticancer Activity of Complexes of the Third Row Transition Metals, Rhenium, Osmium, and Iridium." *Dalton Transact* 47 (2018): 9934-9974.
- Dicpinigaitis, Peter V, Gayle Yvonne E, Solomon Gail, and Gilbert Richard D. "Inhibition of Cough-Reflex Sensitivity by Benzonatate and Guaifenesin in Acute Viral Cough." *Respir Med* 103 (2009): 902-906.
- van Rijt, Sabine H, and Sadler Peter J. "Current Applications and Future Potential for Bioinorganic Chemistry in the Development of Anticancer Drugs." *Drug Discov Today* 14 (2009): 1089-1097.
- Wu, Chuan-De, Hu Aiguo, Zhang Lin, and Lin Wenbin. "A Homochiral Porous Metal-Organic Framework for Highly Enantioselective Heterogeneous Asymmetric Catalysis." *J Am Chem Soci* 127 (2005): 8940-8941.
- Dongare, Pravin R, Gore Anil H, Kondekar Uttam R, and Kolekar Govind B, et al. "A Quinazolinone Based Fluorescent Chemosensor for Selective Detection of Fe (III) in Aqueous Media: Applications to Pharmaceutical and Environmental Analysis." *Inorgan Nano-Metal Chem* 48 (2018): 49-56.
- Qiu, Shilun, and Zhu Guangshan. "Molecular Engineering for Synthesizing Novel Structures of Metal-Organic Frameworks with Multifunctional Properties." *Coordinat Chem Rev* 253 (2009): 2891-2911.
- Zhao, Ying, Deng Dong-Sheng, Ma Lu-Fang, and Ji Bao-Ming, et al. "A New Copper-Based Metal-Organic Framework as a Promising Heterogeneous Catalyst for Chemo-and Regio-Selective Enamination of  $\beta$ -Ketoesters." *Chem Commun* 49 (2013): 10299-10301.
- Nayak, Nagaraj, Prasad Kollur Shiva, Pillai Renjith Raveendran, and Armaković Stevan, et al. "Remarkable Colorimetric Sensing Behavior of Pyrazole-Based Chemosensor Towards Cu (ii) Ion Detection: Synthesis, Characterization and Theoretical Investigations." *RSC Adv* 8 (2018): 18023-18029.
- Raman, N, Ravichandran S, and Thangaraja C. "Copper (II), Cobalt (II), Nickel (II) and Zinc (II) Complexes of Schiff Base Derived from benzil-2, 4-Dinitrophenylhydrazone with Aniline." *J Chem Sci* 116 (2004): 215-219.
- Singh, Kiran, Singh Barwa Manjeet, and Tyagi Parikshit. "Synthesis and Characterization of Cobalt (II), Nickel (II), Copper (II) and Zinc (II) Complexes with Schiff Base Derived from 4-Amino-3-Mercapto-6-Methyl-5-Oxo-1, 2, 4-Triazine." *Euro J Med Chem* 42 (2007): 394-402.
- Liu, Changlin, Wang Ming, Zhang Tianle, and Sun Hongzhe. "DNA Hydrolysis Promoted by Di-and Multi-Nuclear Metal Complexes." *Coord Chem Rev* 248 (2004): 147-168.
- Dhanda, Geetika, Sarkar Paramita, Samaddar Sandip, and Haldar Jayanta. "Battle against Vancomycin-Resistant Bacteria: Recent Developments in Chemical Strategies." *J Med Chem* 62 (2018): 3184-3205.
- Xu, Zhi, Zhao Shi-Jia, Lv Zao-Sheng, and Gao Feng, et al. "Fluoroquinolone-Isatin Hybrids and their Biological Activities." *Euro J Med Chem* 162 (2019): 396-406.
- Chaudhary, Ashu, Agarwal Mithlesh, and Singh R V. "Organotin (IV) and Organolead (IV) Complexes as Biocides and Fertility Regulators: Synthetic, Spectroscopic and Biological Studies." *Appl Organometal Chem* 20 (2006): 295-303.
- Gielen, Marcel. "Organotin Compounds and their Therapeutic potential: A Report from the Organometallic Chemistry Department of the Free University of Brussels." *Appl Organometal Chem* 16 (2002): 481-494.
- Frere, Jean-Marie. "Beta-Lactamases and Bacterial Resistance to Antibiotics." *Mole Microbiol* 16 (1995): 385-395.
- Devasahayam, Gina, Scheld William M, and Hoffman Paul S. "Newer Antibacterial Drugs for a New Century." *Expert Opinion Investigat Drugs* 19 (2010): 215-234.
- Da Settimo, Antonio, Da Settimo Federico, Marini Anna Maria, and Primofiore Giampaolo, et al. "Synthesis, DNA Binding and In Vitro Antiproliferative Activity of Purinoquinazoline, Pyridopyrimidopyrine and Pyridopyrimidobenzimidazole Derivatives as Potential Antitumor Agents." *Euro J Med Chem* 33 (1998): 685-696.
- Sondhi, Sham M, Singh Jaiveer, Rani Reshma, Gupta P P, et al. "Synthesis, Anti-Inflammatory and Anticancer Activity Evaluation of Some Novel Acridine Derivatives." *Euro J Med Chem* 45 (2010): 555-563.
- Sano, Hiroko, Noguchi Tomomi, Tanatani Aya, and Hashimoto Yuichi, et al. "Design and Synthesis of Subtype-Selective Cyclooxygenase (COX) Inhibitors Derived from Thalidomide." *Bioorgan Med Chem* 13 (2005): 3079-3091.
- Lamie, Phoebe F, Philoppes John N, El-Gendy Ahmed O, and Rarova Lucie, et al. "Design, Synthesis and Evaluation of Novel Phthalimide Derivatives as In Vitro Anti-Microbial, Anti-Oxidant and Anti-Inflammatory Agents." *Molecules* 20 (2015): 16620-16642.
- Rezaei, Zahra, Moghimi Setareh, Javaheri Rezvan, and Asadi Mehdi, et al. "Synthesis and Biological Evaluation of 1, 3, 4-Thiadiazole Linked Phthalimide Derivatives as Anticancer Agents." *Lett Drug Design Discover* 14 (2017): 1138-1144.

33. Stewart, Scott G, Spagnolo Daniel, Polomska Marta E, and Sin Melvin, et al. "Synthesis and TNF Expression Inhibitory Properties of New Thalidomide Analogues Derived via Heck Cross Coupling." *Bioorgan Med Chem Lett* 17 (2007): 5819-5824.
34. Noguchi, Tomomi, Fujimoto Haruka, Sano Hiroko, and Miyajima Atsushi, et al. "Angiogenesis Inhibitors Derived from Thalidomide." *Bioorgan Med Chem Lett* 15 (2005): 5509-5513.
35. Amin, Kamelia M, El-masry Afaf H, Mohamed Neama A, and EA Awad Ghada, et al. "Synthesis, Characterization and Antimicrobial Activity of Some Novel Isoindole-1, 3-Dione Derivatives." *Der Pharm Chem* 5 (2013): 97-108.
36. Meng, Xiang-Bao, Han Dong, Zhang Su-Na, and Guo Wei, et al. "Synthesis and Anti-Inflammatory Activity of N-Phthalimidomethyl 2, 3-Dideoxy-and 2, 3-Unsaturated Glycosides." *Carbohydr Res* 342 (2007): 1169-1174.
37. Nossier, Eman S, Fahmy Hoda H, Khalifa Nagy M, and El-Eraky Wafaa I, et al. "Design and Synthesis of Novel Pyrazole-Substituted Different Nitrogenous Heterocyclic Ring Systems as Potential Anti-Inflammatory Agents." *Molecules* 22 (2017): 512.
38. El Shehry, Mohamed F, Ghorab Mostafa M, Abbas Samir Y, Fayed Eman A, et al. "Quinoline Derivatives Bearing Pyrazole Moiety: Synthesis and Biological Evaluation as possible Antibacterial and Antifungal Agents." *Euro J Med Chem* 143 (2018): 1463-1473.
39. Sharath, Vishwanath, Vijay Kumar Honnaiah, and Naik Nagaraja. "Synthesis of Novel Indole Based Scaffolds Holding Pyrazole Ring as Anti-Inflammatory and Antioxidant Agents." *J Pharma Res* 6 (2013): 785-790.
40. Abdallah, Magda A, Gomha Sobhi M, Abbas Ikhlass M, and Kazem Mariam SH, et al. "An Efficient Synthesis of Novel Pyrazole-Based Heterocycles as Potential Antitumor Agents." *Appl Sci* 7 (2017): 785.
41. Tränkle, Christian, Mies-Klomfass Elisabeth, Botero Cid Mario H, and Holzgrabe Ulrike, et al. "Identification of a [3H] Ligand for the Common Allosteric Site of Muscarinic Acetylcholine M2 Receptors." *Mole Pharmacol* 54 (1998): 139-145.
42. Raasch, Alexandra, Scharfenstein Olaf, Tränkle Christian, and Holzgrabe Ulrike, et al. "Elevation of Ligand Binding to Muscarinic M2 Acetylcholine Receptors by Bis (Ammonio) Alkane-Type Allosteric Modulators." *J Med Chem* 45 (2002): 3809-3812.
43. Abdel-Hafez, Atef Abdel-Monem. "Synthesis and Anticonvulsant Evaluation of N-Substituted-Isoindolinedione Derivatives." *Arch Pharma Res* 27 (2004): 495-501.
44. Reja, Sahin, Mukherjee Deboshmita, Das Purak, and Kumar Pranesh, et al. "3-(1, 3-Dioxoisindolin-2-yl)-N, N-Dimethylpropan-1-Ammonium Perchlorate: Synthesis, Crystal Structure, Docking Study and In Vitro Anticancer Activity against the Human Hepatomas Cell Line (Hep G2)." *J Mole Struct* 1245 (2021): 131006.
45. Bender, Wiebke, Staudt Markus, Tränkle Christian, and Mohr Klaus, et al. "Probing the Size of a Hydrophobic Binding Pocket within the Allosteric Site of Muscarinic Acetylcholine M2-Receptors." *Life Sci* 66 (2000): 1675-1682.
46. Duda-Johner, Seraina, Daib Jurgen O, Mohr Klaus, and Tacke Reinhold. "Synthesis and Pharmacological Characterization of New Silicon-Based W84-Type Allosteric Modulators for Ligand Binding to Muscarinic M2 Receptors." *J Organometal Chem* 686 (2003): 75-83.
47. Staudt, Markus, Tränkle Christian, Mohr Klaus, and Holzgrabe Ulrike. "Contribution of Lateral Substituents in Heptane-Bisammonium Derivatives to the Allosteric Stabilization of Antagonist Binding to M2-Receptors." *Life Sci* 62 (1997): 423-429.
48. Holzgrabe, Ulrike, and Heller Eberhard. "A New Synthetic Route to Compounds of the AFDX-Type with Affinity to Muscarinic M2-Receptor." *Tetrahedron* 59 (2003): 781-787.
49. Kowalczyk, Iwona. "Study of N, N-Dimethyl (Carboethoxymethyl)-3-Phthalimidopropylammonium Chloride Dihydrate by DFT Calculations, NMR and FTIR Spectroscopy." *J Mole Struct* 928 (2009): 12-17.
50. Balakrishnan, A, and Sankar A. "Study on the Synthesis, Structure and Antimicrobial activity of the new Mannich base and its Transition Metal Complexes Derived from Phthalimide." *Asian J Res Chem* 11 (2018): 746-750.
51. Worlikar, Shilpa A, and C Larock Richard. "Palladium-Catalyzed One-Step Synthesis of Isoindole-1, 3-Diones by Carbonylative Cyclization of o-Halobenzoates and Primary Amines." *J Organic Chem* 73 (2008): 7175-7180.
52. Orzeszko, Andrzej, Melon-Ksya Dorota, Kowalczyk Ewa, and Czupryński Krzysztof. "Synthesis and Liquid Crystalline Properties of Novel Imides and Thioimides with Chiral Aliphatic Tails." *Zeitschrift Naturforschung B* 58 (2003): 1015-1020.
53. Collin, Xavier, Robert Jean-Michel, Wielgosz Gaétane, and Le Baut Guillaume, et al. "New Anti-Inflammatory N-Pyridinyl (alkyl) Phthalimides Acting as Tumour Necrosis Factor- $\alpha$  Production Inhibitors." *Euro J Med Chem* 36 (2001): 639-649.

**How to cite this article:** Das, Rajesh Kumar, and Reja Sahin. "A Review on Different Synthetic Route and the Medicinal Applications of 2-(3-(Dimethylamino)Propyl) Isoindoline-1,3-Dione Derivatives." *Med Chem* 11 (2021) : 598